Latest NewsJeffrey Jensen, MD, contextualizes contraceptive efficacy in modern trials FlynnAugust 20, 2026 The Pearl Index reported for the newly FDA-approved norelgestromin and ethinyl estradiol transdermal system (Gwyn Lo; Viatris) reflects a shift in how contraceptive efficacy is measured in modern US trials rather than a signal clinicians should find concerning, according to Jeffrey Jensen, MD, MPH, Professor, Obstetrics & Gynecology, Oregon Health & Science University. The discussion continues Jensen’s reaction to the FDA approval of the once-weekly patch.1 ContraceptionHealthcareReproductive rightsUnited States
